Podcasts about digital pathology

Send us a textWhy are so many pathologists still afraid of going digital? In this USCAP special episode sponsored by Muse Microscopy, I talk with Dr. Sarah Dry, Chair of Pathology and Laboratory Medicine at UCLA, about real-world adoption, AI fear, and how change is best managed when it's people-led.From her early digital research lab in 2007 to pioneering innovative workflows at UCLA today, Dr. Dry knows how direct-to-digital imaging and AI can enhance, not replace, our work.

Send us a textWhy is digital pathology progressing faster in some parts of the world than others? In this international episode sponsored by Muse Microscopy, I sit down with Junya Fukuoka and Norman Zerbe—presidents of the Asian and European Societies of Digital Pathology—to unpack how cultural, regulatory, and infrastructural forces are shaping progress differently across continents.From direct-to-digital tissue imaging considered an alternative to frozen sections in Asia, to legal hurdles in Europe, we discuss what's advancing adoption—and what's still holding it back.

Send us a textAt the last  Pathology Visions 2024, I sat down with Imogen Fitt of Signify Research and Nick Best from Pathology News for a candid, energetic recap of what's really shaping the future of digital pathology.We discuss how two pathologists drove digital pathology adoption in their lab,  the reality behind radiology partnerships, the cautionary tale of AI burnout, and how the Technology Buyer's Guide helps pathologists navigate endless scanner options. From standardization and DICOM to staffing crises, remote workflows, and even Meta glasses—we covered it all.

Send us a text“It used to take 40 minutes, now it takes 15” - this is what Dr. Alae Kawam said about her AI-powered prostate biopsy evaluation workflow.  In this energizing episode of the Digital Pathology Podcast recorded at PathVisions 2024, Dr. Alae Kawam joins me to reflect on where pathology is headed—from AI-assisted prostate diagnostics to direct-to-digital imaging and beyond. Together, we unpack what's working, what still feels clunky, and why standardization, staffing flexibility, and smarter AI are critical to the next phase of pathology adoption.

Send us a textWhat does it take to build a digital pathology movement across the most diverse region on Earth?In this episode of the Digital Pathology Podcast, I'm joined by Dr. Junya Fukuoka, practicing pathologist, educator, and founder of the Asian Society of Digital Pathology (ASDP). From Japan to India, Saudi Arabia to South Korea, Asia's digital pathology adoption is growing rapidly—and Dr. Fukuoka is helping lead the charge.We talk about why digital access, multilingual support, and patient advocacy are central to pathology adoption across Asia's diverse regions. We also explore what it means to “skip” a step in tech, and why static images and direct-to-digital imaging may be Asia's most powerful tools.

Send us a textIn this episode, I'm joined by Dr. Hamid Tizhoosh, professor of biomedical informatics at the Mayo Clinic, to unravel what's truly holding back AI in healthcare, especially pathology. From the myths of general-purpose foundation models to the missing link of data availability, this conversation explores the technical and ethical realities of deploying AI that's accurate, consistent, lean, fast, and robust.

Send us a textIn this episode of the Digital Pathology Podcast, I sit down with Dr. Yuri Nikiforov, founder of the World Tumor Registry, to explore how this global, open-access whole slide image platform contributes to cancer diagnostics, education, and research.We talk about how the registry allows pathologists, researchers, and patients to view curated whole-slide images from around the world, starting with thyroid tumors and expanding into other cancers like breast and lung. Learn how AI, molecular diagnostics, and editorial curation come together to build a truly global pathology tool that's free for everyone, forever.

Send us a textIn this episode of the Digital Pathology Podcast, I explore the ethical and bias considerations in AI and machine learning through the lens of pathology. This is part six of our special seven-part series based on the landmark Modern Pathology review co-authored by the UPMC group, including Matthew Hanna, Liam Pantanowitz, and Hooman Rashidi.From data bias and algorithmic bias to labeling, sampling, and representation issues, I break down where biases in AI can arise—and what we, as medical data stewards, must do to recognize, mitigate, and avoid them.

This week's Expert is Jeff McIntyre, Vice President, Liver Programs at the Global Liver Institute. His major topic is how recent high-level FDA job cuts might affect MASH drug and diagnostics development. He also shares reactions to FibroSIGHT, HistoIndex's new digital pathology service for clinical practice. Highlight: Recent job cuts at the FDA will produce chaos in government and slow response to any emerging crises.Second Highlight: Patient self-advocacy becomes even more important in this environment.The conversation takes place on April 1, which lends context to Jeff's opening comment about the rate and nature of change in Washington, DC. He and Roger quickly focus on high-level job cuts at the FDA. Jeff believes that the clearest outcome from these changes is that the government will be less able to respond promptly and in a medically appropriate manner to future health crises. Jeff agrees with former FDA Commissioner Rob Califf's comment that the FDA as we know it "is dead," and that we have little idea what the future holds. A slower-moving, more chaotic government with a Secretary of HHS who minimizes pharmacotherapies for alternative therapies presents a challenge for all SLD patients. Jeff states that patients need to become more vigilant self-advocates (even more than they are today). He also identifies patient advocacy organizations like GLI as a place patients can go to seek the guidance and support they need from patient advocates. Finally, the conversation turns to discuss FibroSIGHT. Jeff describes FibroSIGHT as "exactly where we should be and should not be at the same time," a technology that takes a significant step forward in understanding and patient support, but one that ties us to biopsy as a standard for clinical care. Jeff and Roger agree this issue will play out over the coming years. 

This week's newsmaker, Yukti Choudhury, Director of Clinical Development at HistoIndex, joins Roger Green to discuss FibroSIGHT, a new HistoIndex service that allows clinicians to use HistoIndex's Second Harmonic Generation (SHG) technology and analytics to determine specific CRN fibrosis level for patients with inconclusive NIT results.  One reason FibroSIGHT is worthy of attention: This is the first time an in-depth analysis of clinical trial biopsy results is being placed at the service of clinical treatment. Another reason: Yukti states that demand for this technique could equal 163,000 cases this year, rising to one million by 2028. The interview starts with Yukti sharing information on her own academic and commercial background and how she came to this role. She describes FibroSIGHT, a service that will provide a highly accurate CRN fibrosis level for patients whose NIT results suggest no clear or consistent finding. Yukti provides practical cues on ordering the test and its reimbursement. Roger shares his long-standing respect for SHG and the clarity it produces. He notes the economic benefit of determining whether a patient has F2 fibrosis, which is indicated for pharmacotherapy, vs.F1, which is not indicated. He sees clear benefit in this analysis. Roger goes on to express concern that any option requiring more biopsies will reduce the number of patients treated, particularly if having this tool encourages payers to require a biopsy as a prerequisite to treatment. He asks whether, over time, HistoIndex might be able to develop a companion analytic to improve these estimates without requiring biopsy. 

CME credits: 0.50 Valid until: 04-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/revolutionizing-diagnostic-precision-ai-driven-approaches-in-digital-pathology-and-her2-expression/29878/ With the availability of HER2-directed therapies, it's important to accurately identify patients who would benefit from these therapies, particularly in breast cancer, where we now have a spectrum of HER2 positivity. Advances in technology have augmented the role of digital pathology (DP) and artificial intelligence (AI) in oncologic pathology. This activity demonstrates how DP/AI can be used for more accurate biomarker assessment and explores the impact this may have on patient outcomes.=

Send us a textUSCAP 2025 Daily Update – Day 3 Recap with Dr. Aleksandra ZurawIn this episode of the Digital Pathology Podcast, I bring you Day 3 insights live from USCAP 2025—from moderating the MUSE panel on slide-free imaging to exploring regulatory strategies, tech innovations, and collaborations across the digital pathology community.Get an inside look at how direct-to-digital pathology is transforming workflows, how companies like Techcyte are streamlining AI applications, and why regulatory strategy is as crucial as your scanning tech.

Send us a textUSCAP 2025 Daily Update – Day 4 with Dr. Aleksandra ZurawIt's the final day of USCAP 2025, and in this episode of the Digital Pathology Podcast, I'm sharing personal moments, spontaneous tech wins (and fails), and meaningful conversations with some of the most forward-thinking voices in digital pathology.From running around with mics and misplaced tripods to interviewing Dr. Dry and Dr. Ozumura, this episode captures both the spirit of innovation and the real-world challenges of advancing digital workflows—especially in environments where regulations still lag behind.

Send us a textUSCAP 2025 Daily Update – Day 2 with Dr. Aleksandra ZurawWelcome back to the Digital Pathology Podcast live from USCAP 2025! On Day 2, I dive into the momentum building across the conference—covering major trends, tech insights, and how digital pathology is no longer just a topic, but a critical tool used to deliver sessions and share knowledge.From vendor-driven presentations to real-world applications of AI and slide-free technology, this episode explores how digital workflows are being integrated into education, diagnostics, and collaboration on a global scale.

Send us a textUSCAP 2025 Daily Update – Day 1 Highlights from Dr. Aleksandra ZurawWelcome to the first live daily update from USCAP 2025, recorded straight from the conference floor by Dr. Aleksandra Zuraw, your host at Digital Pathology Place. In this episode, Aleks shares behind-the-scenes moments, exciting vendor previews, and key updates as the world's largest pathology meeting kicks off.

Send us a textIn this episode of the Digital Pathology Podcast, I sit down with Matthew Nuñez, CEO of MUSE Microscopy, to discuss the groundbreaking advancements in direct-to-digital imaging in pathology. Traditional pathology workflows rely on glass slides, formalin fixation, and time-consuming processing steps. But what if we could skip the slide entirely and go straight to digital?

Send us a textHow Can Digital Pathology Workflows Stay Compliant and Efficient?In this episode of the Digital Pathology Podcast, I sit down with Scott Randall, Senior Application Specialist at Hamamatsu (Hamamatsu NanoZoomer), and Amanda Coble, Senior Director of Product for Proscia (Proscia's Website), to discuss the critical role of compliance, interoperability, and efficiency in digital pathology workflows.

Today my guest is Jason Maloney, VP of Customer Experience at Proscia.  What we discuss with Jason: His background in customer-facing roles across various company sizes. Being drawn to Proscia by the opportunity to impact lives through digital pathology. Customer Experience (CX) encompasses professional services, technical support, and customer success, focusing on the post-sale experience. Many companies in the industry focus on product development without adequately addressing customer needs and experiences. Jason applies insights from various industries, emphasizing the importance of treating customers as humans and understanding their workflows. Proscia's CX strategies have led to reduced time to go live with software and improved overall customer satisfaction. Proscia fosters a continuous feedback loop between customers and internal teams, enhancing product development and customer support. Proscia's CX team helps pathologists and researchers integrate AI into their workflows, providing expertise and support. The future focus will be on developing trusted advisor relationships with customers, enhancing customer success initiatives, and deepening problem-solving capabilities.   Links for this episode: Pathologists' Assistant Shadowing Network on LinkedIn Health Podcast Network  LabVine Learning Dress A Med scrubs Digital Pathology Club   Proscia Expanded Customer Experience (CX) Practice Enables Users To Realize Value Over 30% Faster   People of Pathology Podcast: Twitter Instagram

Send us a textWhat if we could skip glass slides altogether and go straight from fresh tissue to digital image? Muse Microscopy's SmartPath device aims to do just that, capturing diagnostic-quality images directly from fresh tissue. In this episode brought to you by Muse Microscopy, I sit down with Dr. Rao and Dr. Edwards to discuss the insights, challenges, and future of this groundbreaking technology. We explore its regulatory ramifications, change management in veterinary and human pathology, and financial feasibility. Tune in to learn why SmartPath could be a game-changer for both pathologists and patients.00:00 Introduction to SmartPath Technology00:54 Meet the Experts: Dr. Rao and Dr. Edwards01:08 FDA Approval and Implementation Plans01:35 Change Management in Pathology01:56 Training Pathologists for SmartPath03:48 Translational Tissue Banking and Clinical Applications04:29 Impact on Breast Pathology05:49 Pathologists' Reception and Adoption14:33 Financial Viability and ROI19:44 Conclusion and Future ProspectsLinks and Resources:This episode on YouTubeMuse Microscopy WebsiteSmartPath Device Demo VideoSupport the showBecome a Digital Pathology Trailblazer get the "Digital Pathology 101" FREE E-book and join us!

Send us a textTransforming Pathology: A Deep Dive into the Muse SystemThis episode is sponsored by Muse Microscopy. In this episode, we explore the primary challenge of implementing digital pathology globally—digitizing the analog. A potential solution is direct-to-digital pathology, exemplified by the MUSE system by Muse Microscopy. This technology eliminates the need for glass slides and manual staining, offering rapid, non-destructive imaging of intact tissue samples. You will learn about the advantages of Muse, including faster diagnostics, improved data fidelity, and broader accessibility, particularly in remote areas. Detailed insights into the Muse workflow, imaging techniques, and potential applications in human and veterinary medicine are provided. Challenges like adoption barriers and regulatory hurdles are also addressed. Join us as we explore how the Muse system is redefining diagnostic workflows and enhancing patient outcomes.00:00 Introduction to Digital Pathology00:18 The Hurdle of Digitizing Analog Pathology00:26 Direct to Digital Pathology: A Game Changer01:46 Introduction to Muse Microscopy02:32 How Direct to Digital Pathology Works03:10 Advantages of Direct to Digital Pathology04:13 Understanding Muse Technology05:26 The Digital Pathology Workflow with Muse14:15 Challenges and Misconceptions15:38 The Future of Pathology16:31 Frequently Asked Questions18:07 Conclusion and Additional Resources18:54 Behind the Scenes and Final ThoughtsLinks and Resources:Original blog post on Digital Pathology Place  Website and LinkedInYouTube playlist with more information about MUSESmartPath Product presentation from CAP 2024Video showing the SmartPath device at the conference boothUSCAP in Boston - Muse Microscopy booth #528Support the showBecome a Digital Pathology Trailblazer get the "Digital Pathology 101" FREE E-book and join us!

Live from Pathology Visions 2024 in Orlando, FL, the Beyond the Scope team interviews past Presidents of the DPA who were in attendance. Guests include:Eric Glassy (2017)Marilyn Bui (2019)Michael Rivers (2020)Anil Parwani (2021)Ester Abels (2022)Liron Pantanowitz (2023)Junya Fukuoka (Current - 2025)Each President answers questions about the current state of Digital Pathology, what DP/AI looks like in 10 years, how DP/AI can impact healthcare, and how to implement in the community setting. Stay tuned at the end to find out which Presidents are cat or dog lovers and their ice cream preference! It is recommended to watch the video version of this episode on the DPA websiteA forum to engage with the hosts and other listeners has been launched on the DPA website www.digitalpathologyassociation.org. DPA members may login to the DPA Collaborate hub (under the Resources tab) and join the Beyond The Scope community. All listeners are encouraged to use this forum to suggest future topics and guests, submit questions and corrections, and provide general feedback.

Send us a textIn this episode of the Digital Pathology Podcast, I take a deeper dive into Generative AI in Pathology, following the AI in Pathology series published by USCAP. AI has already begun transforming medical diagnostics, but what does Generative AI mean for digital pathology? From synthetic data generation to multimodal AI models, this episode explores the cutting edge of AI's role in pathology and how it's evolving to enhance efficiency, accuracy, and patient care.

Send us a textIn this episode of the Digital Pathology Podcast, I explore the evolving role of Generative vs. Non-Generative AI in Medical Diagnostics. As AI continues to transform the medical field, understanding the differences between these two approaches is essential for pathologists, researchers, and healthcare professionals.We break down the key concepts behind generative AI models (like ChatGPT and image-generation tools) and non-generative AI models (such as traditional machine learning for diagnostic support). I also highlight a groundbreaking seven-part AI review series published in Modern Pathology, which serves as a crucial reference for integrating AI into pathology.

Send us a textIn this episode of the Digital Pathology Podcast, I sit down with Dr. Lija Joseph, a pathologist who is redefining patient care by making pathology more accessible and understandable. Traditionally, pathology has been a “behind-the-scenes” specialty, but Dr. Joseph is changing that by directly engaging with patients, showing them their pathology slides, and empowering them with knowledge about their diagnoses.

In this episode of the Exploring Artificial Intelligence (AI) in Oncology series, Waqas Haque, MD, MPH, Hematology/Oncology Fellow at the University of Chicago, speaks with Osama Khan, MD, Staff Pathologist at Natera, a cell-free DNA (cfDNA) technology company that aims to make personalized genetic testing and diagnostics part of the standard of care. Dr. Khan shares insights into how digital pathology and emerging technologies like AI and measurable residual disease (MRD) testing are revolutionizing oncology, driving precision medicine, and enhancing patient care. Learn more at: https://oncdata.com/digital-pathology-osama-khan

Live from PV24 in Orlando, FL, Alae Kawam interviews Dr. Aleks Zuraw. Aleks is a veterinary pathologist and founder of Digital Pathology Place, a website and podcast dedicated to all of the hot topics in digital pathology. Topics of discussion include reflections on PV24, practical applications of digital pathology, and the correlation between radiology and pathology transformation to digital. This episode is produced by David Remedios.A forum to engage with the hosts and other listeners has been launched on the DPA website www.digitalpathologyassociation.org. DPA members may login to the DPA Collaborate hub (under the Resources tab) and join the Beyond The Scope community. All listeners are encouraged to use this forum to suggest future topics and guests, submit questions and corrections, and provide general feedback.

Send us a textWelcome to the 21st edition of DigiPath Digest! In this episode, together with Dr. Aleksandra Zuraw you will review the latest digital pathology abstracts and gain insights into emerging trends in the field. Discover the promising results of the PSMA PET study for prostate cancer imaging, explore the collaborative open-source platform HistioColAI for enhancing histology image annotation, and learn about AI's role in improving breast cancer detection. Dive into topics such as the role of AI in renal histology classification, the innovative TrueCam framework for trustworthy AI in pathology, and the latest advancements in digital tools like QuPath for nephropathology. Stay tuned to elevate your digital pathology game with cutting-edge research and practical applications.00:00 Introduction to DigiPath Digest #2101:22 PSMA PET in Prostate Cancer06:49 HistoColAI: Collaborative Digital Histology12:34 AI in Mammogram Analysis17:21 Blood-Brain Barrier Organoids for Drug Testing22:02 Trustworthy AI in Lung Cancer Diagnosis30:09 QuPath for Nephropathology35:30 AI Predicts Endocrine Response in Breast Cancer40:04 Comprehensive Classification of Renal Histologic Types45:02 Conclusion and Viewer EngagementLinks and Resources:Subscribe to Digital Pathology Podcast on YouTubeFree E-book "Pathology 101"YouTube (unedited) version of this episodeTry Perplexity with my referral linkMy new page built with PerplexityHistoColAI Github PagePublications Discussed Today:

Send us a textIn this episode of the Digital Pathology Podcast, you will learn about cytology's entrance into the digital pathology space, including successful AI and scanner implementations. We cover AI's role in rapid on-site evaluation for lung cancer and share insights on a looming prostate cancer surge and how digital pathology and AI can help. IYou will also listen to a live demo of me using an AI assistant to decode a scientific paper in real-time. Tune in to stay on top of the digital pathology research in 2025!00:00 Welcome to DigiPath Digest00:53 Introduction and New Year Greetings01:41 Diving into DigiPath Digest01:44 AI in Respiratory Cytology06:11 The Role of AI in Pathology09:49 Multi-Omics and AI11:28 Radiomics and Pathomics14:44 Live Q&A and Future Plans20:09 Prostate Cancer Tsunami22:34 Thyroid Cytology and Live AI-Assistant demo31:07 Conclusion and the option to send texts :)Links and Resources:Subscribe to Digital Pathology Podcast on YouTubeFree E-book "Pathology 101"YouTube (unedited) version of this episodeTry Perplexity with my referral linkMy new page built with PerplexityPublications Discussed Today:

Send us a textLeveraging AI for Deep Insights into Tertiary Lymphoid Structures in Colorectal CancerIn this episode of the Digital Pathology Podcast, I introduce 'Aleks + AI,' a new experimental series leveraging Google's Notebook LM to delve deeper into scientific literature. Today's focus is on tertiary lymphoid structures (TLS) and their potential to predict colorectal cancer prognosis. We discuss a study published in the October 2024 issue of Precision Clinical Medicine, exploring different methods of quantifying TLS using digital pathology and AI.  The paper title is: "Comparative analysis of tertiary lymphoid structures for predicting survival of colorectal cancer: a whole-slide images-based study"The findings highlight TLS density as a reliable predictor of survival and its correlation with immune responses and microsatellite instability. We also touch upon the potential for AI to streamline TLS analysis in clinical settings and the broader implications for personalized medicine. Join us as we dive into the intersection of digital pathology and computer science, featuring insights and commentary from my AI co-hosts, Hema and Toxy.00:00 Welcome and Introduction00:45 Introducing the New AI Tool: Notebook LM by Google01:11 Experimental Series: "Aleks + AI"02:06 Deep Dive into Tertiary Lymphoid Structures (TLS)03:18 Understanding TLS and Their Role in Colorectal Cancer04:20 Quantification Methods and Key Findings05:02 Implications for Personalized Medicine09:02 AI in TLS Analysis and Future Prospects11:00 CMS Classification and TLS Density12:08 Study Limitations and Future Directions15:40 Final Thoughts and Wrap-Up16:28 Feedback and Future PlansTHIS EPISODE'S RESOURCES116: DigiPath Digest #18 | Federated Learning in Pathology. Developing AI Models While Preserving PrivacyPUBLICATION DISCUSSED TODAY

Send us a textIn this episode, I'm joined by Dr. Giovanni Lujan, Nick Best, and Dr. Alae Kawam to explore a topic that hits close to home for many of us in digital pathology: why do so few pathologists attend digital pathology conferences? We delve into the barriers, opportunities, and actionable solutions that can help bridge this gap and drive the adoption of digital pathology across the profession.What You'll Hear in This Episode:Startling Observations (00:02:00): Only 10% of attendees at some digital pathology conferences are pathologists. Why is this the case, and what does it mean for the future of the field?Barriers to Adoption (00:04:00): From time constraints to a lack of institutional support, we unpack the key challenges stopping pathologists from going digital.Mentorship and Collaboration (00:09:00): How mentorship programs can connect seasoned professionals with early-career pathologists to share knowledge and drive adoption.The Role of the Next Generation (00:15:00): Insights into how young pathologists can lead the way with their enthusiasm and fresh perspectives.Engaging the Skeptics (00:07:00): Strategies to introduce hesitant or resistant pathologists to the transformative power of digital tools.Global Comparisons (00:10:00): What can the U.S. learn from Europe and Asia about accelerating digital pathology adoption?Leveraging Leadership and Advocacy (00:19:00): How young pathologists can work with leadership to introduce digital pathology as a standard practice in their organizations.The Impact of Digital Pathology on Work-Life Balance (00:20:00): Exploring how remote sign-outs and shorter turnaround times can enhance both patient care and pathologists' quality of life.Making Digital Pathology the Norm (00:24:00): Ideas for shifting digital pathology from a secondary option to the standard of care, addressing common fears and misconceptions.Future Plans and Next Steps (00:28:00): A look at actionable steps for advancing digital pathology through podcasts, mentorship, and departmental advocacy.Key Takeaways:This conversation isn't just about identifying challenges—it's about solutions. We discuss how collaboration, leadership, and individual responsibility can drive meaningful change in digital pathology. Whether you're a seasoned pathologist or just starting your career, this episode offers inspiration and actionable ideas to make digital pathology a core part of the profession.Connect With Us:Share your thoughts on why more pathologists aren't attending these conferences. What's holding them back, and what changes would you like to see in your department? Let's keep this important conversation going!Support the showBecome a Digital Pathology Trailblazer get the "Digital Pathology 101" FREE E-book and join us!

Send us a textIn today's DigiPath Digest, we delve into federated learning, a decentralized approach to AI training that preserves data privacy. I discuss recent papers from PubMed and share my experiences experimenting with AI tools like Perplexity and Gemini for research efficiency. You will also get updates on upcoming plans, including leveraging AI to share more podcasts with you. Did I mention that this is the last livestream of the year as I head to Poland for Christmas? No More DigiPath Digests. We got to number 18 (I overestimated it a bit in the podcast), and you have been instrumental in continuing this series!Big THANK YOU to all the digital Pathology #TRLBLZRS showing up every Friday morning for this!Join me as we tackle the nuances of federated learning and its impact on healthcare and pathology.00:00 Introduction and Greetings00:18 Today's Topic: Federated Learning00:57 AI Tools and Updates04:39 Federated Learning in Detail08:03 Challenges and Benefits of Federated Learning11:21 Exploring More Papers and Future Plans22:53 Wrapping Up and Final ThoughtsLinks and Resources:Subscribe to Digital Pathology Podcast on YouTubeFree E-book "Pathology 101"YouTube (unedited) version of this episodeTry Perplexity with my referral linkMy new page built with PerplexityPublications Discussed Today:

Send us a textThis episode features a conversation with Dr. Richard Doughty, Senior Medical Advisor at Aiforia Technologies, whose dual training in veterinary and medical pathology offers a unique perspective on the intersections of these fields. Together, we explore the challenges, opportunities, and innovations shaping digital pathology today.What You'll Learn in This Episode:[00:00:00] Challenges in Pathology TodayDiscussing the pathologist shortage, delayed diagnoses, and how AI can address these issues.[00:03:00] A Pathologist's Dual PerspectiveDr. Doughty shares his journey of becoming both a veterinary and medical pathologist, and what this means for pathology innovation.[00:08:00] AI's Role in PathologyInsights into how clinician-centric AI tools like Aiforia are designed to improve diagnostic workflows and outcomes.[00:14:00] Addressing Challenges in AI IntegrationStrategies for overcoming hurdles like algorithm aversion, skill retention, and fostering trust in AI systems.[00:22:00] Preparing Future PathologistsThe importance of incorporating AI training into residency programs and creating a digitally savvy workforce.[00:44:00] How to Implement AI EffectivelyPractical advice on selecting tools, collaborating with providers, and setting realistic goals for AI adoption in practice.Resources and Links Mentioned:Learn More About Aiforia: https://www.aiforia.com/Download Digital Pathology 101Contact Dr. Richard Doughty: richard.doughty@aiforia.comWatch more videos created together with Aiforia: VIDEO PLAYLISTThis episode is supported by Aiforia Technologies, leaders in AI-powered solutions for digital pathology.Do you know someone who should listen to this episode? Share it with them!Support the showBecome a Digital Pathology Trailblazer get the "Digital Pathology 101" FREE E-book and join us!

Dr. Steven Hart is a Senior Associate Consultant in AI at Mayo Clinic who has played a key role in shaping genomics and digital pathology with GenomeGPS, Mayo Clinic's primary DNA sequencing workflow. His groundbreaking contributions have led to advancements in understanding inherited cancer risk and improving digital pathology workflows. With over 100 peer-reviewed publications, Dr. Hart's innovative algorithms are driving efficiency in genetic predisposition testing, reducing unnecessary procedures, and enhancing precision healthcare. We had some audio issues for this one which we tried to fix but they're still pretty apparent so apologies for that D:! 00:00:00 - Introduction  00:01:09 - From a factory worker to a leader in AI and medicine 00:05:11 - Proving people wrong as a motivator 00:06:37 - Crazy factory stories 00:07:38 - Why Mayo Clinic? 00:09:52 - Surprising things about Mayo Clinic 00:11:33 - Is Mayo Clinic's data high quality? 00:12:55 - How to prepare healthcare for AI (and why AI won't actually have the biggest impact) 00:20:50 - Democratizing pathology with AI  00:25:38 - Will AI replace pathologists? 00:29:24 - How do you judge how well an embedding works?  00:33:22 - Reducing expectations for diagnostic AI usage in healthcare 00:36:46 - How do you keep up with the rapidly evolving pace of AI? 00:38:31 - OpenAI o1 and prompt hacking  00:41:27 - Are we close to artificial general intelligence?  00:47:03 - How helpful are regulatory agencies like the FDA with translating AI? 00:49:52 - What makes a good question? 00:53:33 - Favorite parts about living in Rochester, MN 00:55:14 - What gives your life meaning?  00:58:36 - Advice for young people in uncertain times Host: Nathan Keller Twitter: @NathanKellerX Linkedin: https://www.linkedin.com/in/nathankeller1/ Producer: Saurin Kantesaria Linkedin: Saurin Kantesaria --- Support this podcast: https://podcasters.spotify.com/pod/show/maml-podcast/support

Send us a textIn this episode, I sit down with Dr. Nina Kottler, Associate Chief Medical Officer of Clinical AI at Radiology Partners, to dive into the evolving role of AI in radiology and how it can shape the future of digital pathology. Dr. Kottler shares her unique journey, expertise, and practical frameworks for implementing AI that enhance patient care and streamline diagnostic workflows.Episode Highlights and Key Moments:[00:00:45] Introduction to Dr. Nina KottlerDr. Kottler discusses her background in applied mathematics, her journey into medicine, and her work at Radiology Partners, where she combines clinical practice with AI innovation.[00:04:30] Breaking Down Complex Problems in AINina explains her approach to tackling large clinical challenges by breaking them down into manageable parts, a method that's essential for developing and optimizing AI solutions.[00:08:15] The Role of Data OrchestrationWe dig into “data orchestration” and how ensuring data is aligned with the right AI model is key to producing accurate and reliable clinical outcomes.[00:11:45] Life Cycle of an Exam in RadiologyNina takes us through each step in the radiology workflow—from the initial patient consultation to reporting—and highlights how AI can streamline and enhance each phase.[00:17:00] Evolution of AI Models in HealthcareWe explore how AI has evolved, from early CAD systems to today's multimodal and transformer models, and the exciting possibilities they bring to both radiology and pathology.[00:23:20] Addressing the Lag in AI Adoption in HealthcareWe discuss the challenge of keeping up with AI advancements while balancing patient safety, regulatory standards, and the need for reliability in clinical settings.[00:27:50] Frameworks for Reducing Variability and Improving AccuracyNina shares actionable frameworks that Radiology Partners uses to reduce variability and improve diagnostic precision—strategies that pathology can learn from.[00:32:40] AI in Workflow Optimization: Where It Has Real ImpactWe discuss specific use cases in clinical workflows that show where AI can bring the greatest value, especially in enhancing patient care through optimized processes.[00:36:50] The Power of Multimodal AI and Vision-Language ModelsCombining large language models with computer vision is moving diagnostics closer to comprehensive, AI-driven care—a promising development we explore in depth.[00:42:15] The Future of Agents in AIWe dive into the concept of “agents” in AI and how these systems may soon coordinate multiple models for more complex and precise clinical analyses.[00:48:10] Where to Learn More about Dr. Nina Kottler's WorkNina shares where you can catch her upcoming talks and presentations, plus resources for staying updated on the latest in AI for radiology and digital pathology.If you're a pathologist, radiologist, or healthcare professional curious about AI's impact on diagnostics, this episode is packed with practical guidance on integrating AI into clinical workflows. Join us as we explore how AI is shaping the future of radiology and pathology!Support the showBecome a Digital Pathology Trailblazer get the "Digital Pathology 101" FREE E-book and join us!

Send us a textWelcome back to the DigiPath Digest, fresh from PathVision! In this episode we will dive into the latest updates from the PathVision conference, covering trends in AI-driven diagnostics, the expansion of digital pathology into primary care, and the exciting new frontier of glassless pathology.Join me as I recap the highlights of PathVision and the latest updates from the digital pathology literature, including discussions on:AI Integration in Pathology: Learn how AI is advancing breast cancer diagnostics with tools like Ki-67 scoring models and multi-label AI for mammography, aimed at reducing unnecessary biopsies.Global Health & Digital Microscopy: Hear about innovative projects from Sweden and Finland focused on AI-supported digital microscopy in primary healthcare labs, bringing accessible diagnostics to underserved areas.Glassless Pathology with MUSE: Discover how glassless pathology is changing tissue imaging with MUSE (Microscopy with UV Surface Excitation), enabling diagnostics without the need for traditional glass slides. Dr. Zuraw breaks down what this means for future pathology workflows.Plus, a shout-out to the vendors and partners making these advancements possible, and insights from Dr. Zuraw's conversations with digital pathology trailblazers from around the globe, including new developments from Asia in digital pathology education and technology.Timestamps:[0:00] PathVision Highlights & Global Attendees[5:15] AI in Diagnostic Workflows: Dr. Anil Parwani's “Pathology Train Ride”[12:30] Moving Beyond Narrow AI: Multimodal and Foundational Models[18:45] Glassless Pathology: A New Frontier with MUSE Microscopy[25:10] Integrating Digital Microscopy in Global Health Labs[32:00] Breast Cancer Month: New Advances in AI for Diagnostics[42:00] One Health & AI for Disease Detection in Primary Care[48:30] Special Interviews: Jun Fukuoka and Asian Society of Digital PathologyLinks and Resources:Subscribe to Digital Pathology Podcast on YouTubePathology News Signify Research Monthly RecapYouTube version of this episodePublications Discussed Today:

My guest today is Jon Odle from Pramana. What we discuss with Jon: Overview of Pramana and its scanning technology Importance of QA/QC in digital pathology Challenges in scaling digital pathology, including labor costs The role of AI in digital pathology and its potential as a diagnostic aid The concept of Digital Pathology as a Service (DPAAS) Advantages of DPAAS, including cost-effectiveness and reduced labor The Mayo Clinic project to digitize 12 million slides Challenges faced during the Mayo project, including slide quality issues The importance of interoperability and standardization in digital pathology Future plans for Pramana Links for this episode: Health Podcast Network  LabVine Learning Dress A Med scrubs Digital Pathology Club   Pramana Inside the Digitization of Mayo Clinic's Tissue Registry Archive   People of Pathology Podcast: Twitter Instagram

Send us a textIn this episode, I meet with Adam Cole, MD, and Jason Camilletti about how digital pathology transforms the field. Adam, the CEO of TruCore Pathology, and Jason, the CEO of PathNet Labs, share their unique journeys from the military to becoming digital pathology leaders. We explore their experiences, challenges, and innovations in integrating AI and digital tools into their practices.Key Topics Discussed:[00:00:00] Introduction to AI in Pathology[00:01:00] Adam and Jason's Military Backgrounds[00:05:00] Adam's Story of Becoming a Mobile Pathologist[00:10:00] The Move to Fully Digital Pathology[00:14:30] AI's Role in Pathology[00:20:00] Challenges in Implementing Digital Pathology[00:25:00] Improving Patient Outcomes with Digital Tools[00:29:00] Digital Pathology's Impact on Patient Care[00:38:00] Using AI for Quantifying Tumor Volume[00:40:00] The Role of AI in Enhancing DiagnosticsAdam and Jason emphasize the immense potential of AI in pathology, but also the need for thoughtful integration. The future of pathology lies in using digital tools to provide faster, more accurate diagnoses while maintaining the critical human element. Tune in to learn how AI is reshaping the field and what it means for both pathologists and patients.THIS EPISODE'S RESOURCES:TruCore websitePathNet WebsiteOTHER EPISODES YOU MIGHT LIKE:The Evolution of Digital Pathology – from Improved Histology Quality to Fair Use of Pathology Data w/ Matthew O. Leavitt, DDx FoundationAchieving work-life balance in medicine as a pathologist with digital pathology w/ Todd Randolph, MD Support the showBecome a Digital Pathology Trailblazer get the "Digital Pathology 101" FREE E-book and join us!

Send us a textWhat does the FDA jurisdiction for LDTs mean for the labs? Do they need to worry? How do they need to change the way they operate?In this episode, I talk with Dr. Thomas Nifong, a clinical pathologist and VP of CDX operations at Acrovan Therapeutics, about the recent FDA ruling on laboratory-developed tests (LDTs) issued on May 6th, 2024. We discuss the implications of considering LDTs as medical devices, requiring regulation, and explore the authority of FDA versus CLIA. The conversation also covers historical contexts, practical implications of regulatory changes, and the roles of organizations like CAP, ACLA, and AMP in legal challenges against the FDA. We dive into the differences in requirements between CLIA and FDA, New York's alternative approval route, and potential impacts on lab operations and compliance. Join us for an insightful conversation filled with essential information for those in the field of molecular pathology.00:00 Introduction and Special Guest Announcement00:24 FDA's New Rule on Laboratory Developed Tests (LDTs)01:58 Recording the Podcast: A Casual Lunch Conversation03:47 Understanding FDA's Authority Over Medical Devices08:07 Disputes and Legal Challenges12:03 Practical Implications and Industry Reactions12:47 Understanding FDA's Focus: Safety and Efficacy14:11 The Role of CMS and Medical Necessity14:48 Congressional Involvement and Legal Authority16:06 Impact on Labs and Future LDTs18:33 Quality Systems and Compliance20:16 Modifications and Software Updates21:16 Conclusion and Next StepsSupport the showBecome a Digital Pathology Trailblazer get the "Digital Pathology 101" FREE E-book and join us!

Send us a textIn this episode, I had a fascinating conversation with Candice Chu, DVM, PhD, DACVP, about how artificial intelligence (AI) is reshaping veterinary diagnostics and education. Candice, a clinical pathologist and educator at Texas A&M, is using AI tools like ChatGPT to improve efficiency in clinical workflows and academic processes. We explored the practical applications of AI, ethical concerns, and its future impact on veterinary medicine.Key Topics Discussed:[00:00:00] Introduction to AI in Veterinary Education and DiagnosticsI ask Candice how AI is changing veterinary education and diagnostics, and she explains how AI is boosting efficiency in both areas.[00:01:00] Candice's Journey in Veterinary MedicineCandice shares her journey from Taiwan to the U.S., her career in veterinary pathology, and becoming an educator at Texas A&M.[00:05:00] Custom GPT Model for Clinical PathologyCandice describes the development of her custom GPT model for clinical pathology and its role in improving diagnostic efficiency.[00:10:00] AI Tools for Academic and Clinical EfficiencyWe talk about how AI tools reduce repetitive tasks, giving professionals more time for critical thinking and decision-making.[00:14:30] Ethical Concerns When Using AI in Veterinary MedicineCandice emphasizes the ethical responsibility of using AI, highlighting the importance of human judgment in AI-assisted diagnostics.[00:20:00] How Veterinary Students Can Leverage AICandice shares tips on how students can use AI to enhance learning, from simplifying research to generating case questions.[00:29:00] AI's Role in Academic Writing and Veterinary PracticeWe discuss how AI tools streamline academic writing and research, and how AI will continue shaping veterinary practice in the future.[00:39:00] Critical Thinking and AI in Veterinary MedicineCandice and I conclude by discussing how critical thinking and professional responsibility are essential when using AI tools.Candice highlighted the transformative role AI can play in both veterinary education and diagnostics, improving efficiency while requiring responsible use. While AI tools like ChatGPT offer many benefits, the human element—our critical thinking and judgment—remains crucial in ensuring accurate results and ethical practices.This episode provides practical insights on how veterinary professionals, educators, and students can harness AI to streamline workflows and improve diagnostic accuracy. Be sure to listen to the full conversation for actionable tips on integrating AI into your practice!EPISODE RESOURCES:About Dr. Candice Chu (Including her social media and achievements)Candice's PaperUndermind AIYoutube Episode of this EpisodeSupport the showBecome a Digital Pathology Trailblazer get the "Digital Pathology 101" FREE E-book and join us!

Send us a textIn this episode, Dr. Richard Fox shares how AI is transforming veterinary diagnostics. From his early career to the world of AI, Dr. Fox offers practical insights into the challenges, opportunities, and innovations that AI brings to pathology. Tune in to learn how AI is enhancing workflow efficiency, diagnostic precision, and the future direction of veterinary pathology.[00:00] Introduction – Introduction to Dr. Richard Fox and his expertise in veterinary pathology and AI.[03:00] Dr. Fox's Career Journey – His shift from veterinary practice to pathology and AI.[08:00] Entering the AI Space – How Dr. Fox became involved in AI, including his work with Aiforia.[15:00] AI in Diagnostics – AI's impact on diagnostic workflows and speeding up tasks.[22:00] Quality Control in AI Models – Ensuring AI model accuracy and the importance of data consistency.[28:00] AI Model Validation Challenges – Overcoming issues with model validation and retraining.[35:00] Integrating AI into Workflows – How AI fits into veterinary pathology workflows and practical considerations.[40:00] Future of AI in Pathology – Predictions on the future trends in AI and on-premises diagnostics.[50:00] Common Questions About AI – Addressing concerns like AI replacing pathologists and optimizing workflows.[58:00] Conclusion – Key takeaways and how to get started with AI in veterinary diagnostics.The Episodes Resources:Contact AiforiaRichard Fox's LinkedIn Profile Richard Fox's Email Support the showBecome a Digital Pathology Trailblazer get the "Digital Pathology 101" FREE E-book and join us!

Send us a textIn this 14th episode of DigiPath Digest, I introduce a new course on AI in pathology, designed to help pathologists understand and confidently navigate AI technologies. The episode focuses on various research studies that highlight the integration and effectiveness of AI in pathology, particularly in colorectal biopsies and kidney transplant biopsies, emphasizing the importance of seamless workflow integration. You will also learn about challenges in manual assessment of tumor-infiltrating lymphocytes and HER2 expression in breast cancer. I  advocate for more consistent and precise AI-driven approaches. And there an opportunity for a discounted beta test of the new AI course.00:00 Welcome to DigiPath Digest #1400:24 New AI Course Announcement01:51 Deep Learning in Colorectal Biopsies09:17 AI in Kidney Biopsy Evaluation16:12 Automated Scoring of Tumor Infiltrating Lymphocytes24:22 AI for HER2 Expression in Breast Cancer31:13 Conclusion and Course DetailsTHIS EPISODE'S RESOURCES

Send us a textGood morning, digital pathology trailblazers! Welcome to another exciting exploration of digital pathology and AI. I'm thrilled to have our global community here with us today from so many different time zones. Before we dive into today's content, a quick note: my equipment is being a bit finicky, but that's life in the digital world!Integrating Image Analysis with AILet's kick off with a recap of some recent updates. Yesterday, I had the privilege of presenting to a mixed group at Cincinnati Children's Hospital. We discussed AI in image analysis, an essential tool bridging radiology and pathology as these fields rapidly evolve with new technologies like foundation models and large language models. A diverse audience—ranging from radiologists to pathologists—prompted me to adapt my presentation style on the spot. It was a dynamic discussion about the advancements in healthcare that shared perspectives from both sides.Lymphovascular Invasion: A Case StudyOur first paper today focuses on a deep learning model for identifying lymphovascular invasion (LVI) in lung adenocarcinoma. This significant prognostic factor is crucial for advancing diagnostic consistency and reliability. Unlike broad foundation models, this work engages with dedicated image analysis applications targeting specific diagnostic challenges. The study demonstrated reduced pathologist evaluation time by nearly 17% and even more in complex cases, aligning with previous findings that AI enhances efficiency by around 21%.AI Collaborations: Human and Veterinary PathologyNext, we delve into a collaborative effort between human and veterinary pathologists, emphasizing the promise of AI integration in telepathology and digital pathology. These fields are converging to enhance information exchange, teaching, and research. I'm particularly excited about this paper due to my own veterinary pathology background and the potential it offers for both educational and clinical practices.Spatial Profiling and Immuno-OncologyWe then journey into the intricate landscape of immuno-oncology with a study on PD-1 and PD-L1 in osteosarcoma microenvironments. Utilizing deep learning and multiplex fluorescence immunohistochemistry, researchers highlighted the spatial orchestration of these markers, providing insights into potential immunotherapeutic strategies. This work is an exemplar of how AI can illuminate complex biological landscapes, offering a path for future therapies.ConclusionThank you all for joining this vibrant discussion. Whether you're tuning in from early morning in Atlanta or late at night in Algeria, your engagement enriches our learning experience. Keep an eye out for more content and upcoming courses designed to unpack these groundbreaking developments in AI and digital pathology.Until next time, keep blazing trails in digital pathology!Support the showBecome a Digital Pathology Trailblazer get the "Digital Pathology 101" FREE E-book and join us!

Send us a textThe episode explores the concept of blind review, a process designed to eliminate hindsight bias by allowing medical experts to evaluate cases without knowing the outcome or the hiring party. Stephanie Franckewitz, JD, MBA, founder of Blind Review, discusses its application in legal cases, particularly for digital pathology and radiology. By providing an unbiased expert opinion, blind review aids the defense and plaintiff parties in court, increasing the chances of a favorable verdict. Stephanie outlines her journey from a medical malpractice defense lawyer to starting Blind Review and highlights the potential for digital pathology to revolutionize the legal process, reduce bias, and improve case outcomes. Collaboration with platforms like PathPresenter enables pathology slides to be reviewed efficiently and effectively within a legal context. This approach benefits both defendants and plaintiffs by ensuring objective evaluations and enhancing the credibility of expert testimonies in trials.00:00 Introduction to Blind Review01:19 The Role of Digital Pathology in Legal Cases02:16 Stephanie Franke Reid's Journey07:19 Challenges in Traditional Expert Reviews10:09 Implementing Blind Review in Pathology18:16 Collaboration with PathPresenter25:43 Streamlining the Legal Process with Digital Pathology26:51 Collaborative Tools for Legal Experts27:20 Path Presenter: A Game Changer for Attorneys28:17 Understanding Pathology for Juries29:20 Streamlining Case Preparation with Path Presenter31:54 Setting Up a Blind Review Process35:38 The Gold Standard of Blind Review41:53 Impact of Blind Review on Legal Outcomes49:49 Empowering Legal and Medical Professionals54:50 Conclusion and Call to Action - contact StephanieTHIS EPISODE'S RESOURCESStephanie's LinkedIn ProfileThe Blind Review WebsiteSupport the showBecome a Digital Pathology Trailblazer get the "Digital Pathology 101" FREE E-book and join us!

Send us a textIn this episode, I celebrate another milestone of the Digital Pathology Place YouTube channel that was achieved thanks to you, my digital pathology trailblazer, reflecting on its journey since its inception in 2019. I delve into the developments in digital pathology, focusing on the first video I ever published on YouTube about AI in pathology, highlighting trends, tools, and challenges in the field. The video was based on a presentation I gave on the day I got engaged, so if you want to know the whole story listen in.I explain key concepts like - artificial intelligence, - machine learning, and - deep learning, and discuss - How could AI eventually support pathology practice despite current challenges?00:00 Welcome and AI Co-Host Feedback00:19 YouTube Monetization Milestone01:18 Reflecting on the First Video02:47 Special Day and Personal Story05:06 Introduction to AI in Pathology07:26 AI Terminology and Concepts13:17 Current Status of AI in Pathology17:33 Challenges and Future of AI in Pathology22:42 Conclusion and Call to Action23:30 Updates and Future PlansTHIS EPISODE'S RESOURCESThe YouTube version of "AI in Pathology" first videoThe updated "Artificial Intelligence in Pathology" video (coming soon in podcast version)Support the showBecome a Digital Pathology Trailblazer get the "Digital Pathology 101" FREE E-book and join us!

Send us a textIn this episode of DigiPath Digest you will learn about the development of AI models for glaucoma screening using fundus images, the use of AI in detecting metastatic deposits in colorectal cancer, and leveraging immunofluorescence data to reduce pathologist annotation requirements.  Dr. Aleks also invited two AI Co-hosts and shared personal reflections on AI's role in the industry and invites feedback from listeners on AI-generated content.00:00 Introduction to the Livestream Disaster00:24 AI to the Rescue: Enhancing Audio Quality00:38 Meet the AI Co-Hosts01:04 Welcome to the Digital Pathology Podcast01:30 Technical Difficulties and Audience Interaction02:49 Exploring AI in Veterinary Medicine04:34 Hybrid Convolutional Neural Network for Glaucoma Screening07:49 Model for Detecting Metastatic Deposits in Lymph Nodes11:23 Leveraging Immunofluorescence Data for Lung Tumor Segmentation18:05 AI-Generated Content and Future Plans21:37 AI Co-Hosts Take Over32:42 Conclusion and Audience FeedbackTODAY'S EPISODES RESOURCES

Send us a textIn this episode of DigiPath Digest, we review the latest AI developments in digital pathology described in the literature. I explore how AI is pushing the boundaries of metastasis detection, breast cancer treatment predictions, lung cancer research trends, and the creation of pathology foundation models. Episode Breakdown:00:00 – Welcome & Introduction00:36 – Sentinel Node Metastasis Detection: A discussion on the development of an AI model that can detect sentinel node metastasis in melanoma with accuracy comparable to that of pathologists. The model aids in distinguishing between nodal metastasis and intra-nodal nevus, which is crucial for accurate staging in melanoma patients.05:01 – Predicting Breast Cancer Treatment Response: A cross-modal AI model that integrates pathology images and ultrasound data is explored. This model is designed to predict a breast cancer patient's response to neoadjuvant chemotherapy, providing personalized insights that can guide treatment decisions.09:59 – Global Trends in AI and Lung Cancer Pathology: This section reviews a bibliometric study that analyzed global research trends in AI-based digital pathology for lung cancer over the past two decades. The study highlights the need for increased collaboration between institutions and countries to further AI advancements in this area.13:30 – Pathology Foundation Models: An in-depth look at a new foundation model in pathology, designed to generalize across various diagnostic tasks. This model shows significant promise in cancer diagnosis and prognosis prediction, outperforming traditional deep learning methods by addressing domain shifts across different datasets.20:08 – Domain Shifts in AI Models: A brief discussion on the impact of domain shifts, such as variations in staining protocols and patient populations, on the performance of AI models in pathology. Strategies for mitigating these challenges are highlighted.29:09 – Faster Annotation in Pathology: The episode concludes with a review of a study comparing manual and semi-automated annotation methods. The semi-automated approach significantly reduces the time required for annotating whole slide images, offering a more efficient solution for pathologists.Resources Mentioned:

In this podcast episode, healthcare industry experts from AWS and Philips explore the critical intersection of clinical innovation, cloud technology and healthcare delivery. Ashwini Davison, MD, CMIO, Enterprise Imaging Strategy at Amazon Web Services (AWS), and Martijn Hartjes, Clinical Informatics Business Leader at Philips, delve into the urgent need to ease the burden on clinicians and harness integrated diagnostics to enhance patient care.This episode is sponsored by Amazon Web Services (AWS).

Welcome to healthsystemCIO's interview with Dr. Mustafa Yousif, Director of Digital Pathology, and Assistant Professor in the Department of Pathology, at Michigan Medicine. Dr. Yousif has been at the forefront of a groundbreaking digital transformation in pathology at Michigan Medicine, leading efforts to implement a comprehensive digital pathology system over the past 24 months. In […] Source: Road to Digital Pathology Smoother with Enterprise IT Partnership: An In-Depth Discussion with Mustafa Yousif, MD, Director of Digital Pathology, Michigan Medicine on healthsystemcio.com - healthsystemCIO.com is the sole online-only publication dedicated to exclusively and comprehensively serving the information needs of healthcare CIOs.

This conversation contains the first half of Roger Green's interview with PharmaNest Founder and CEO Mathieu Petitjean. After Matt tells the audience a little about his background and PhramaNest, the two discuss what Matt considered the key strategic takeaways for PharmaNest from the various EASL Congress presentations, abstracts and discussions. Before answering the question, Matt describes the core services his company offers: "PharmaNest specializes in digital pathology. Four years ago, we put down the hypothesis that the histological phenotype of fibrosis should be quantified in a high-resolution, sophisticated way." He goes on to state their core proposition for MASLD: "The big idea here is that fibrosis equals phenotype." He proceeds to describe his offerings in greater detail before offering the underlying value of computed histology: fibrosis is a continuous variable that is scored in discrete categories under the NASH-CRN model that drives FDA analysis. With this as context, he answers the question by describing three kinds of MASLD clinical trial designs. The first, earliest trials had a single pathologist reading histological slides. The method is not precise, but the drugs were not very good, and none were ultimately approved. The second set of trials relied on more rigorous methods for pathologists to read histology slides, with multiple readers and robust adjudication systems. Also, the drugs in this second set of trials were more efficacious, so that NASH-CRN, while a blunt instrument, could adequately assess efficacy. For the third set of trials, Matt believes non-invasive tests (NITs) are likely to suffice.

Welcome to the Life Science Success Podcast! In this episode, host Don interviews Catherine from Jellox Biotech at Bio Interntional June of 2024. Catherine shares insights into her journey from financial engineering to the life sciences field, her experience in investment banking, and her current role in business development at Jellox Biotech. She discusses Jellox Biotech's groundbreaking 3D imaging technology for digital pathology, its benefits for early cancer diagnosis, and the company's expansion plans. Catherine also sheds light on the challenges and hopes for the future, especially regarding raising venture capital and global outreach.     00:00 Introduction and Guest Welcome 00:07 Catherine's Background and Career Journey 00:43 Introduction to Jellox Biotech 01:11 Innovations in 3D Imaging and Digital Pathology 02:22 Product Development and Market Expansion 03:56 Challenges and Goals at Bio Conference 08:06 Global Expansion Plans 09:37 Future Aspirations and Technological Impact 15:39 Conclusion and Farewell